Overview

* Kymera Q2 revenue misses analyst expectations, net income also missed, per LSEG data

* Co remains well-capitalized with $1 bln cash, strategic partnership with Gilead

Outlook

* Company has cash runway into second half of 2028

* Kymera's Gilead partnership could yield up to $750 mln

Result Drivers

* GILEAD PARTNERSHIP - Strategic partnership to develop CDK2 degraders, with potential payments up to $750 mln

* CASH POSITION - Well-capitalized with $1 bln cash, providing runway into the second half of 2028

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $11.48 $23.40

Revenue mln mln (19

Analysts

)

Q2 EPS -$0.95

Q2 Net Miss -$76.61 -$66.80

Income mln mln (18

Analysts

)

Q2 $96.03

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Kymera Therapeutics Inc ( KYMR ) is $60.00, about 32.3% above its August 8 closing price of $40.62

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)